Advancis Pharmaceutical to Announce Second Quarter 2006 Financial Results on August 2, 2006
27 July 2006 - 12:14AM
PR Newswire (US)
Conference Call and Webcast to Follow GERMANTOWN, Md., July 26
/PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation
(NASDAQ:AVNC), a pharmaceutical company focused on developing and
commercializing novel anti-infective products, today announced it
will release results for the quarter ended June 30, 2006, on
Wednesday, August 2, 2006, before the market opens. A full text
copy of the release will be disseminated at that time. Edward M.
Rudnic, Ph.D., president and chief executive officer, will host a
conference call to discuss the results and other corporate
developments at 10:30 AM ET on Wednesday, August 2, 2006. Also
participating on the call will be Robert C. Low, vice president,
finance and acting CFO. To participate in the conference call, dial
the appropriate number below shortly before the 10:30 AM start time
and ask for the Advancis Pharmaceutical conference call hosted by
Dr. Rudnic. The teleconference dial-in numbers are as follows:
Domestic callers 1-800-813-8504 International callers
1-706-643-7752 The conference call will be broadcast simultaneously
and archived on the Company's web site,
http://www.advancispharm.com/. Investors should go to the web site
at least 15 minutes early to register, download, and install any
necessary audio software. A replay of the call will be available on
Wednesday, August 2, 2006, beginning at 12:30 PM ET and will be
accessible until Wednesday, August 9, 2006, at 5:00 PM ET. The
replay call-in number is 1-800-642-1687 for domestic callers and
1-706-645-9291 for international callers. The access number is
3476789. About Advancis Pharmaceutical: Advancis Pharmaceutical
Corporation (NASDAQ:AVNC) is a pharmaceutical company focused on
the development and commercialization of anti-infective drug
products that fulfill substantial unmet medical needs in the
treatment of infectious disease. The Company is developing
anti-infective drugs based on its novel biological finding that
bacteria exposed to antibiotics in front- loaded staccato bursts,
or "pulses," are killed more efficiently than those under standard
treatment regimens. Based on this finding, Advancis has developed a
proprietary, once-a-day pulsatile delivery technology called
PULSYS(TM). By examining the resistance patterns of bacteria and
applying its delivery technologies, Advancis has the potential to
redefine infectious disease therapy and significantly improve drug
efficacy, shorten length of therapy, and reduce drug resistance
versus currently available antibacterial products. For more on
Advancis, please visit http://www.advancispharm.com/. DATASOURCE:
Advancis Pharmaceutical Corporation CONTACT: Bob Bannon, Senior
Director, Investor Relations of Advancis Pharmaceutical Corp.,
+1-301-944-6710 or Web site: http://www.advancispharm.com/
Copyright
Advancis (NASDAQ:AVNC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Advancis (NASDAQ:AVNC)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Advancis Pharmaceutical (MM) (NASDAQ): 0 recent articles
More Advancis Pharmaceutical (MM) News Articles